Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

<< Back
Jan 04, 2017

ZIOPHARM to Present at the 35th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2017 at 7:30 a.m. PT.

To access a live audio webcast of the presentation, please visit the Investor Relations section at The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immunotherapy programs, in collaboration with Intrexon Corporation (NYSE:XON), includes viral and non-viral approaches to deliver viral and cell-based therapeutic candidates for investigational treatment of liquid and solid tumors. The Company is advancing programs in multiple stages of development including Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to precisely modulate gene expression. The Company's pipeline includes adenoviral- and cell-based therapeutics in both clinical and preclinical testing, some of which are being advanced in collaboration with MD Anderson Cancer Center.


Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.

David Pitts
Argot Partners